project . 2022 - 2024
Funder: EC Project Code: 101025901
Overall Budget: 172,932 EURFunder Contribution: 172,932 EUR
Open Access mandate for Publications and Research Data
Partners: FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE
Metastatic prostate cancer (mPC) is a lethal disease. Androgen deprivation therapy is the mainstay of patient care. In addition, DNA repair defects is a novel therapeutic target in mPC. However, resistances invariably arise, triggered most of the times by tumor genomic ...